News
September 15, 2024
BIOIO validates its in silico Gene2Drug MOAT module in models of Rheumatoid arthritis. MOAT identified a chemical mimic of IKBz inhibition (Pubmed: 39279148).
April 26, 2024
BIOIO adds Ildiko Lingvay, MD, a pioneering clinical trialist for the GLP-1 RAs and Professor at Univ. of Texas Southwestern to its Scientific Advisory Board.
January 26, 2024
Missouri Technology Corporation, a for-profit public private partnership awarded BIOIO seed funding in its January 2024 investment cycle.
May 9, 2022
BIOIO-2001 was funded by VitaDAO using Molecule’s IP-NFT framework.